First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 17, ...

In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, discusses treatment options for chronic kidney disease patients with ...

As ESRD patients represent the largest market segment in renal anemia, we look forward to initiating our first clinical trial in dialysis patients and are confident that the Phase IIa study results ...

MISGAV, Israel and LONDON, March 27 /PRNewswire/ -- Medgenics (AIM: MEDG) is pleased to announce that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial ...

Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia. NEW ORLEANS—Intravenous (IV) iron and erythropoietin are equally effective ...

For cancer patients, anemia can be a debilitating problem that negatively influences their overall quality of life and worsens their prognosis. The condition is caused either by the cancer itself or ...

Leuven, Belgium − Many patients with a chronic disease or cancer have to contend with anemia − and the severe fatigue that accompanies anemia impedes the patient considerably in his or her daily ...

CINCINNATI, Ohio — Akebia Therapeutics on Tuesday said it started its first Phase I human study (pdf) of a pill meant to help create new red blood cells in anemia patients. The drug, AKB-6548, is an ...

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...

EPO, an important drug for treating anemia, can now be produced in higher quantities and with better quality in mammalian cells designed using CRISPR. To many people, EPO rhymes with doping and ...

FibroGen Inc., a small private biotechnology company in South San Francisco, could reap as much as $815 million in a licensing deal it announced Friday for its two experimental drugs to treat anemia.